AbbVie is trading at $290.56, up +3.13%, with no confirmed company announcement explaining the October 15 move.
- JPMorgan raised its price target to $300 from $285 and maintained an Overweight rating ahead of AbbVie’s Q3 report; Cantor Fitzgerald also raised its target to $290. These actions may be supportive, but reporting does not establish them as the cause.
- AbbVie’s $1.73 dividend went ex-dividend October 15, but that is not a clear explanation for the gain.